Rubicon Share Price Today: Healthcare Stock Jumps On Acquisition Update,Up 33% Since IPO | Buy or Sell?

Rubicon Share Price Today: Rubicon Research's share price has surged nearly 3% after the healthcare firm announced its entry into the Indian CNS formulations market with a latest acquisition. The stock has surged around 33% since its IPO listing in October.

Rubicon Research's share price was trading 3.2% higher at Rs 850.9 per share on BSE at 10:37 am on Thursday, with a market capitalisation of Rs 14,047.69 crore.

Rubicon Research Share Price Recommendation

Rubicon Research's latest acquisition, Arinna Lifescience (Arinna), would help the firm to make inroads into the central nervous system (CNS) therapy in India's branded market (DF). The recent acquisition includes gaining access to an established network of distributors, stockists, and retail pharmacies in India, along with a strong prescriber base, noted Motilal Oswal in its report

"We find this acquisition to be a logical move, as it provides Rubicon's innovative US pipeline of commercialised as well as underdevelopment products with access to a key market in the form of India,' stated Motilal Oswal in its report.

Rubicon Research Target Price

The brokerage has given a 'Buy' recommendation to the Rubicon Research share price, with a target price of Rs 955, with a 16% upside in the long term. "We raise our P/E multiple to 37x (from 35x earlier) to factor in the potential upside from this acquisition. Accordingly, we revise our TP to INR955. Reiterate BUY."

Rubicon Research Share Price Trend

Rubicon Research's share price opened higher on Thursday. It had touched a 52-week high mark of Rs 887.95 per share on November 18, 2025. The stock dipped to its 52-week low mark of Rs 571 per share on October 24, 2025. The stock value has surged 25% year-to-date (YTD). The stock value has surged close to 33% since its IPO listing in October.

Rubicon Research Acquisition

Rubicon Research Limited, on Wednesday, announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited ("Arinna"). The Ahmedabad-headquartered company has a portfolio of over 60 brands in chronic therapies. One of the key highlights of the firm is focused on drugs treating conditions of the central nervous system ("CNS") with more than 4,000 prescribers backed by an established distribution network of distributors, stockists and retail pharmacies in India.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.